Recent REVB News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/19/2024 08:02:22 PM
- Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity • Business Wire • 06/24/2024 01:00:00 PM
- Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini • Business Wire • 06/13/2024 01:21:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 • Business Wire • 05/10/2024 08:52:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 • Business Wire • 03/22/2024 08:15:00 PM
- Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 03/13/2024 01:00:00 PM
- Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference • Business Wire • 03/12/2024 01:00:00 PM
- Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini • Business Wire • 03/04/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:05 AM
- Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 02/13/2024 02:00:00 PM
- Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 03:19:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:01:23 PM
- Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering • Business Wire • 02/05/2024 09:41:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2024 09:06:10 PM
- Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering • Business Wire • 02/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:21:32 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/30/2024 08:32:42 PM
- Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 01/30/2024 02:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/29/2024 10:32:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:18:01 PM
- Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 • Business Wire • 01/23/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/22/2023 10:06:53 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 06:23:34 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM